Urol. praxi. 2022;23(2):73-75

Non-metastatic castration-resistant prostate cancer

MUDr. Jana Katolická, Ph.D.
Onkologicko­‑chirurgické oddělení, FN u sv. Anny, Brno

Metastatic castration-resistant prostate cancer is the incurable form of prostate cancer, carrying the poorest prognosis, and can develop from non-metastatic castration-resistant prostate cancer. There have been three trials assessing treatments in the specific setting of nmCRPC; PROSPER (enzalutamide), SPARTAN (apalutamide), ARAMIS (darolutamide). The results include the delay of metastatic disease development, prevention of symptoms, and a benefit in overall survival.

Keywords: non­‑metastatic castration­‑resistant prostate cancer, enzalutamide, apalutamide, darolutamide.

Received: February 16, 2022; Revised: February 16, 2022; Accepted: February 16, 2022; Prepublished online: February 16, 2022; Published: June 1, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Katolická J. Non-metastatic castration-resistant prostate cancer. Urol. praxi. 2022;23(2):73-75.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Lokeshwar SD, Klaassen Z, Saad F. Treatment and trials in non­‑metastatic castration­‑resistant prostate cancer. Nat Rev Urol. 2021;18(7):433-442. doi: 10.1038/s41585-021-00470-4. Go to original source... Go to PubMed...
    2. Scher HI, Morris MJ, Stadler WM, et al. Trial design and objectives for castration­‑resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology. 2016;34(12):1402.Další literatura u autorky a na www.urologiepropraxi.cz Go to original source... Go to PubMed...
    3. Maha H, Fizazi K, Saad F, et al. PROSPER: A phase 3, randomized, double­‑blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration­‑resistant prostate cancer (M0 CRPC). 2018:3-3. Go to original source...
    4. Smith MR, Saad F, Chowdhury S, et al. Apalutamide treatment and metastasis­‑free survival in prostate cancer. New England Journal of Medicine. 2018;378(15):1408-1418. Go to original source... Go to PubMed...
    5. Fizazi K, Shore N, Teuvo L, et al. Darolutamide in nonmetastatic, castration­‑resistant prostate cancer. New England Journal of Medicine 2019;380(13):1235-1246. Go to original source... Go to PubMed...
    6. Small EJ, Saad F, Chowdhury S, et al. Apalutamide and overall survival in non­‑metastatic castration­‑resistant prostate cancer. Annals of Oncology. 2019;30(11):1813-1820. Go to original source... Go to PubMed...
    7. Sternberg CN, Fizazi K, Saad F, et al. Enzalutamide and Survival in Nonmetastatic, Castration­‑Resistant Prostate Cancer. New England Journal of Medicine. 2020.
    8. ERLEADA, 60MG TBL FLM 120, O lécích.cz (olecich.cz).
    9. NUBEQA, 300MG TBL FLM 112, O lécích.cz (olecich.cz).
    10. www.ema.europa.eu/en/documents/product­‑information/erleada­‑epar­‑product­‑information_cs.pdf.
    11. www.ema.europa.eu/en/documents/product­‑information/nubeqa­‑epar­‑product­‑information_cs.pdf.
    12. www.ema.europa.eu/en/documents/product­‑information/xtandi­‑epar­‑product­‑information_cs.pdf.

    Return to the content


    Urology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.